3737 — Zhongzhi Pharmaceutical Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapContrarian

Market Cap
HK$734.06m
Enterprise Value
HK$732.97m
Revenue
CNY2.21bn

Annual income statement for Zhongzhi Pharmaceutical Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,747	1,826	2,050	2,215	1,737
Cost of Revenue
Gross Profit	1,064	1,070	1,221	1,285	946
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,678	1,689	1,834	2,061	1,713
Operating Profit	68.9	137	215	154	24.4
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	61.8	131	208	147	19
Provision for Income Taxes
Net Income After Taxes	52.4	107	164	96.1	17.7
Minority Interest
Net Income Before Extraordinary Items
Net Income	52.1	106	163	95.2	17.3
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	52.1	106	163	95.2	17.3
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.062	0.125	0.192	0.112	0.021
Dividends per Share